- Home
- CSR vs PHAT Comparison
CSR vs PHAT Comparison
Compare CSR & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- PHAT
- Stock Information
- Founded
- CSR 1970
- PHAT 2018
- Country
- CSR United States
- PHAT United States
- Employees
- CSR N/A
- PHAT N/A
- Industry
- CSR Real Estate Investment Trusts
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- PHAT Health Care
- Exchange
- CSR Nasdaq
- PHAT Nasdaq
- Market Cap
- CSR 965.4M
- PHAT 963.9M
- IPO Year
- CSR N/A
- PHAT 2019
- Fundamental
- Price
- CSR $59.82
- PHAT $13.25
- Analyst Decision
- CSR Buy
- PHAT Strong Buy
- Analyst Count
- CSR 7
- PHAT 5
- Target Price
- CSR $68.57
- PHAT $17.60
- AVG Volume (30 Days)
- CSR 127.3K
- PHAT 1.1M
- Earning Date
- CSR 11-03-2025
- PHAT 10-30-2025
- Dividend Yield
- CSR 5.15%
- PHAT N/A
- EPS Growth
- CSR N/A
- PHAT N/A
- EPS
- CSR 1.82
- PHAT N/A
- Revenue
- CSR $273,450,000.00
- PHAT $147,190,000.00
- Revenue This Year
- CSR $5.77
- PHAT $218.38
- Revenue Next Year
- CSR $1.53
- PHAT $87.14
- P/E Ratio
- CSR $32.79
- PHAT N/A
- Revenue Growth
- CSR 5.72
- PHAT 460.30
- 52 Week Low
- CSR $52.76
- PHAT $2.21
- 52 Week High
- CSR $75.92
- PHAT $19.05
- Technical
- Relative Strength Index (RSI)
- CSR 52.57
- PHAT 53.02
- Support Level
- CSR $58.92
- PHAT $13.11
- Resistance Level
- CSR $60.87
- PHAT $14.22
- Average True Range (ATR)
- CSR 1.33
- PHAT 0.98
- MACD
- CSR -0.03
- PHAT -0.11
- Stochastic Oscillator
- CSR 59.90
- PHAT 23.87
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.